Hospital
Clhg-Oakdale, LLC
Clhg-Oakdale, LLC was paid $2.50M by Medicaid between Jan 2018 and Dec 2024, across 75 billing codes. Its largest line is 99284, emergency room visit (serious) — 34% of everything it billed.
33Billing provider infoCLHG-OAKDALE, LLC
OAKDALE, LA 71463
OAKDALE, LA 71463
33aNPI1104873710assigned 05/28/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.50M
24GClaims68,715
24DCodes billed75
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#62 of 96
Median peer was paid$5.17M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,542 | $167K | |
| 2019 | 6,685 | $167K | |
| 2020 | 4,122 | $91K | |
| 2021 | 10,365 | $287K | |
| 2022 | 15,128 | $474K | |
| 2023 | 15,987 | $749K | |
| 2024incomplete | 9,886 | $568K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 34% | 6,078 | 5,357 | $849K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 7,182 | 6,448 | $600K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 1,983 | 1,747 | $389K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 2.4% | 1,203 | 1,054 | $61K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.4% | 2,633 | 2,141 | $60K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.9% | 2,146 | 1,814 | $48K |
| 80053 | Comprehensive metabolic panel | 1.8% | 8,075 | 6,814 | $46K |
| 80050 | General health panel | 1.7% | 1,089 | 985 | $41K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 511 | 409 | $41K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 9,943 | 8,191 | $40K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 79 | 69 | $36K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 925 | 816 | $26K |
63 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.0% | 745 | $25K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 840 | $23K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 797 | $21K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 69 | $18K |
| 80061 | Lipid panel | <1% | 1,720 | $18K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 639 | $15K |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,580 | $10K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,270 | $10K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 220 | $9K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 65 | $9K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 480 | $9K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 19 | $8K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 693 | $8K |
| 82607 | <1% | 600 | $8K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 77 | $7K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 334 | $5K |
| 83880 | <1% | 282 | $5K | |
| 81003 | <1% | 3,624 | $5K | |
| 84484 | <1% | 799 | $5K | |
| 83735 | <1% | 983 | $5K | |
| 84439 | <1% | 583 | $4K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 162 | $4K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 83 | $3K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 269 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 119 | $3K |
| 81025 | <1% | 358 | $2K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 43 | $2K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 29 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,125 | $2K |
| 93041 | <1% | 49 | $2K | |
| J3490 | Unclassified drugs | <1% | 572 | $2K |
| 82553 | <1% | 320 | $2K | |
| 94762 | <1% | 38 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 34 | $1K |
| 82550 | <1% | 304 | $871.38 | |
| 83690 | <1% | 148 | $674.03 | |
| 87400 | <1% | 82 | $663.47 | |
| 84481 | <1% | 52 | $652.02 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 144 | $650.20 |
| 82746 | <1% | 47 | $646.80 | |
| 82150 | <1% | 125 | $517.35 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 295 | $506.47 |
| J1335 | Injection, ertapenem sodium, 500 mg | <1% | 35 | $431.24 |
| 81001 | <1% | 230 | $390.16 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 16 | $349.92 |
| 85730 | <1% | 118 | $331.64 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 32 | $329.43 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 26 | $325.40 |
| 84436 | <1% | 54 | $289.52 | |
| 85610 | <1% | 123 | $252.76 | |
| 83540 | <1% | 53 | $252.33 | |
| 83550 | <1% | 27 | $231.77 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 16 | $230.01 |
| 87449 | <1% | 19 | $204.20 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 44 | $201.75 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 18 | $156.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 135 | $155.10 |
| 80178 | <1% | 29 | $138.81 | |
| 87070 | <1% | 14 | $129.09 | |
| 87040 | <1% | 16 | $103.20 | |
| 83605 | <1% | 16 | $80.99 | |
| 83874 | <1% | 15 | $52.52 | |
| 94664 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFRAZIER, JAMES (CEO)